Kardigan, a Phase 2b/3 biotech developing in-licensed therapies for cardiovascular diseases, raised $400 million by offering 25 million shares at $16, the high end of the $14 to $16 range. The company offered 1.7 million more shares than anticipated.
Kardigan is advancing three late-stage product candidates: danicamtiv, an oral cardiac myosin activator in a Phase 2b/3 trial for genetic dilated cardiomyopathy caused by MYH7 and TTN gene variants; ataciguat, an oral soluble guanylate cyclase activator in a Phase 2b trial targeting calcific aortic valve stenosis progression; and tonlamarsen, a subcutaneous antisense oligonucleotide administered once monthly that targets hepatic angiotensinogen for blood pressure management in post-hospitalization acute severe hypertension. Kardigan also operates the Prolaio platform, a proprietary data and analytics system incorporating FDA-cleared algorithms and wearable sensor integration designed to collect continuous real-world physiologic data from patients during clinical trials.
The Princeton, NJ-based company will trade on the Nasdaq under the symbol KARD. J.P. Morgan, Jefferies, Leerink Partners, and TD Cowen acted as joint bookrunners on the deal.
Cardiovascular diseases biotech Kardigan prices upsized IPO at $16, the high end of the range
June 18, 2026

